MetaCap

Biomea Fusion (BMEA) vs Dogwood Therapeutics (DWTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biomea Fusion (BMEA) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 41.5% versus a loss of 83.7%. Over five years, BMEA leads with a -95.2% price change compared with -99.2% for DWTX. Biomea Fusion is the larger company by market cap ($41.7 million vs $39.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMEA-41.51%DWTX-83.68%
+135%+21%-94%
Nov 21, 20251 yearNov 20, 2026
BMEA-94.67%DWTX-99.25%
+298%+90%-118%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMEA versus DWTX key metrics
MetricBMEADWTX
Share price$0.5744$1.04
Market cap$41.75M$39.57M
1-day change-2.38%-2.36%
YTD return-53.68%-75.12%
1-year return-41.51%-83.68%
5-year return-95.21%-99.16%
P/E ratio (TTM)—0.10
EPS (TTM)$-0.10$10.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-61.80M$-34.26M
52-week high$2.24$7.04
52-week low$0.45$0.901
Distance from 52-week high-74.32%-85.31%
Analyst consensusbuynone
Avg. price target upside+1118.66%+1252.66%
Average volume2.22M89.88K
Shares outstanding72.68M38.23M
Employees378
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BMEA has outperformed DWTX by 42.2 percentage points over the past year.

About Biomea Fusion

BMEA stock →

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Dogwood Therapeutics

DWTX stock →

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

BMEA vs DWTX FAQ

Which is bigger, Biomea Fusion or Dogwood Therapeutics?

Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $39.57M for Dogwood Therapeutics (DWTX).

Which stock has performed better over the past year, BMEA or DWTX?

BMEA returned -41.51% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.

Are Biomea Fusion and Dogwood Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons